HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ruggero De Maria Selected Research

Ataxia Telangiectasia (Louis Bar Syndrome)

11/2019Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
1/2018CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ruggero De Maria Research Topics

Disease

120Neoplasms (Cancer)
03/2024 - 07/2003
18Colorectal Neoplasms (Colorectal Cancer)
06/2023 - 01/2007
18Breast Neoplasms (Breast Cancer)
10/2022 - 05/2004
13Glioblastoma (Glioblastoma Multiforme)
03/2024 - 12/2005
8Neoplasm Metastasis (Metastasis)
03/2022 - 08/2011
8Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2021 - 11/2013
7Colonic Neoplasms (Colon Cancer)
12/2020 - 01/2007
6Lung Neoplasms (Lung Cancer)
07/2022 - 01/2014
6Glioma (Gliomas)
01/2017 - 12/2005
6Male Breast Neoplasms (Male Breast Cancer)
10/2016 - 09/2014
5Melanoma (Melanoma, Malignant)
01/2024 - 06/2012
5Triple Negative Breast Neoplasms
10/2020 - 12/2015
5Prostatic Neoplasms (Prostate Cancer)
01/2015 - 03/2010
5Leukemia
06/2014 - 05/2010
5Thyroid Neoplasms (Thyroid Cancer)
11/2010 - 10/2003
4Disease Progression
01/2023 - 12/2008
3Obesity
11/2020 - 09/2010
3Carcinogenesis
07/2019 - 09/2010
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
06/2014 - 01/2008
3Anemia
11/2013 - 07/2003
3Multiple Myeloma
11/2012 - 01/2008
3Anaplastic Thyroid Carcinoma
08/2009 - 05/2007
2Adenocarcinoma of Lung
12/2021 - 11/2019
2COVID-19
10/2021 - 06/2020
2Ductal Carcinoma
12/2020 - 07/2016
2Adenocarcinoma
08/2020 - 10/2014
2Infections
06/2020 - 01/2017
2Hematologic Neoplasms (Hematological Malignancy)
01/2020 - 11/2012
2Ataxia Telangiectasia (Louis Bar Syndrome)
11/2019 - 01/2018
2Stomach Neoplasms (Stomach Cancer)
01/2018 - 01/2017
2Rare Diseases (Rare Disease)
08/2017 - 11/2014
2Uterine Cervical Neoplasms (Cancer of the Cervix)
06/2016 - 01/2016
2Residual Neoplasm
12/2015 - 10/2003
2Chordoma
07/2013 - 09/2006
2Thrombocytopenia (Thrombopenia)
10/2011 - 05/2007
2Polycythemia Vera
02/2009 - 05/2006

Drug/Important Bio-Agent (IBA)

19Proteins (Proteins, Gene)FDA Link
10/2022 - 10/2003
18Biomarkers (Surrogate Marker)IBA
01/2024 - 09/2010
12MicroRNAs (MicroRNA)IBA
03/2020 - 01/2008
10Phosphotransferases (Kinase)IBA
01/2022 - 06/2007
8CytokinesIBA
01/2022 - 02/2006
7Hormones (Hormone)IBA
01/2019 - 09/2010
6pertuzumabIBA
01/2021 - 01/2017
5Trastuzumab (Herceptin)FDA Link
10/2022 - 10/2014
5ErbB Receptors (EGF Receptor)IBA
01/2022 - 12/2011
5Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
07/2018 - 06/2012
5Messenger RNA (mRNA)IBA
01/2017 - 12/2008
5LigandsIBA
10/2012 - 11/2004
5Interleukin-4 (Interleukin 4)IBA
08/2009 - 10/2003
4DNA (Deoxyribonucleic Acid)IBA
11/2021 - 07/2015
4Interleukin-10 (Interleukin 10)IBA
08/2009 - 10/2003
4Death Domain ReceptorsIBA
05/2007 - 05/2004
3Immune Checkpoint InhibitorsIBA
01/2024 - 01/2020
3Ado-Trastuzumab EmtansineIBA
01/2021 - 01/2017
3IntegrinsIBA
12/2020 - 06/2013
3AntagomirsIBA
03/2020 - 01/2008
3Antineoplastic Agents (Antineoplastics)IBA
08/2019 - 06/2008
3Oncogene Proteins (Oncogene Protein)IBA
06/2016 - 06/2007
3Androgen Receptors (Androgen Receptor)IBA
11/2015 - 01/2013
3Androgen Antagonists (Antiandrogens)IBA
11/2015 - 11/2014
3Estrogen ReceptorsIBA
11/2015 - 10/2014
3Gonadotropin-Releasing Hormone (GnRH)FDA Link
05/2015 - 09/2014
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2015 - 12/2010
3Caspase 8 (Caspase-8)IBA
05/2010 - 12/2005
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
05/2007 - 11/2004
2Histone Deacetylase InhibitorsIBA
03/2024 - 10/2014
2C-Reactive ProteinIBA
04/2022 - 10/2021
2human ERBB2 proteinIBA
01/2022 - 01/2021
2Interferon Type IIBA
01/2022 - 01/2017
2AnthracyclinesIBA
01/2022 - 03/2015
2prexasertibIBA
04/2021 - 01/2018
2AntigensIBA
01/2020 - 03/2002
2Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
11/2019 - 01/2018
2CateninsIBA
10/2017 - 03/2014
2Fluorouracil (Carac)FDA LinkGeneric
10/2017 - 09/2010
2Phenobarbital (Luminal)FDA Link
04/2016 - 10/2014
2Aromatase InhibitorsIBA
05/2015 - 09/2014
2Cyproterone AcetateIBA
05/2015 - 11/2014
2TOR Serine-Threonine KinasesIBA
07/2013 - 06/2012
2Aldehyde DehydrogenaseIBA
11/2012 - 11/2010
2Therapeutic UsesIBA
11/2012 - 12/2005
2Stem Cell FactorIBA
10/2011 - 05/2007
2Temozolomide (Temodar)FDA LinkGeneric
04/2010 - 12/2008
2Small Interfering RNA (siRNA)IBA
06/2008 - 02/2006
2Bortezomib (Velcade)FDA Link
01/2008 - 05/2007
2InterleukinsIBA
06/2007 - 02/2006
2Neutralizing AntibodiesIBA
02/2006 - 10/2003
1UracilIBA
03/2024
1pyridineIBA
03/2024
1metachromin VIBA
06/2023

Therapy/Procedure

59Therapeutics
03/2024 - 01/2007
33Drug Therapy (Chemotherapy)
03/2024 - 07/2003
7Neoadjuvant Therapy
10/2022 - 10/2014
6Radiotherapy
03/2024 - 12/2008
6Immunotherapy
01/2023 - 01/2015
5Precision Medicine
07/2022 - 01/2015
3Lasers (Laser)
08/2020 - 03/2013
2Molecular Targeted Therapy
07/2013 - 01/2011
2Heterologous Transplantation (Xenotransplantation)
08/2010 - 04/2010
1Biological Therapy
03/2024